This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Opiant Pharmaceuticals Dividendo
Dividendo criteri di controllo 0/6
Opiant Pharmaceuticals does not have a record of paying a dividend.
Informazioni chiave
n/a
Rendimento del dividendo
n/a
Rapporto di remunerazione
Rendimento medio del settore | 2.2% |
Prossima data di pagamento dei dividendi | n/a |
Data di stacco del dividendo | n/a |
Dividendo per azione | n/a |
Utile per azione | -US$6.28 |
Previsione del rendimento del dividendo | n/a |
Aggiornamenti recenti sui dividendi
Nessun aggiornamento
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Insufficient data to determine if OPNT's dividends per share have been stable in the past.
Dividendo in crescita: Insufficient data to determine if OPNT's dividend payments have been increasing.
Rendimento dei dividendi rispetto al mercato
Opiant Pharmaceuticals Rendimento dei dividendi rispetto al mercato |
---|
Segmento | Rendimento dei dividendi |
---|---|
Azienda (OPNT) | n/a |
Fondo del 25% del mercato (US) | 1.4% |
Top 25% del mercato (US) | 4.3% |
Media del settore (Pharmaceuticals) | 2.2% |
Analista previsionale (OPNT) (fino a 3 anni) | n/a |
Dividendo notevole: Unable to evaluate OPNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividendo elevato: Unable to evaluate OPNT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Distribuzione degli utili agli azionisti
Copertura degli utili: Insufficient data to calculate OPNT's payout ratio to determine if its dividend payments are covered by earnings.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Unable to calculate sustainability of dividends as OPNT has not reported any payouts.